Eleven sites open for patient enrollment in TakeAim CLL combination study with zanubrutinib; Company reaffirms guidance for dosing of initial five patients by end of July 2026 with data expected December 2026; Stockholders approve reverse stock split LEXINGTON, Mass., June 26, 2026...
Hence then, the article about curis announces eleven active clinical sites in takeaim cll study reaffirms patient dosing guidance and reports stockholder approval of reverse stock split was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split )
Also on site :
- MAGA Influencer Scott Presler Denied Entry To GOP Event, Blames Thune
- Amazon’s 'Elegant' 3-Piece Rattan Patio Set Is a Coastal Summer Upgrade That's Now Just $75 for Prime Day
- Quote of the Day: Yogi Berra on Why 'A Nickel Ain't Worth a Dime' Anymore